Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dicycloplatin injection in metastatic castration-resistant prostate cancer
CTR20170903Phase 2Active
- Sponsor
- Beijing Xingda Science System
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dicycloplatin in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Beijing Xingda Science System. Started Aug 2017; status: active.
02
Drugs
dicycloplatin
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20170903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170903.